@article{185165b780e347829e1335ccb1fe8879,
title = "Better survival is observed in cervical cancer patients positive for specific anti-glycan antibodies and receiving brachytherapy",
abstract = "Objective: To measure anti-glycan antibodies (AGA) in cervical cancer (CC) patient sera and assess their effect on therapeutic outcome. Patients and methods: Serum AGA was measured in 276 stage II and 292 stage III Peruvian CC patients using a high content and throughput Luminex multiplex glycan array (LMGA) containing 177 glycans. Association with disease-specific survival (DSS) and progression free survival (PFS) were analyzed using Cox regression. Results: AGAs were detected against 50 (28.3%) of the 177 glycans assayed. Of the 568 patients, 84.5% received external beam radiation therapy (EBRT) plus brachytherapy (BT), while 15.5% only received EBRT. For stage-matched patients (Stage III), receiving EBRT alone was significantly associated with worse survival (HR 6.4, p < 0.001). Stage III patients have significantly worse survival than Stage II patients after matching for treatment (HR = 2.8 in EBRT+BT treatment group). Furthermore, better PFS and DSS were observed in patients positive for AGA against multiple glycans belonging to the blood group H, Lewis, Ganglio, Isoglobo, lacto and sialylated tetrarose antigens (best HR = 0.49, best p = 0.0008). Conclusions: Better PFS and DSS are observed in cervical cancer patients that are positive for specific antiglycan antibodies and received brachytherapy.",
keywords = "Anti-glycan antibodies, Biomarkers, Cervical cancer, Glycans, Therapeutic outcome",
author = "Sharad Purohit and Ferris, {Daron G.} and Manual Alvarez and Tran, {Paul M.H.} and Tran, {Lynn K.H.} and Mysona, {David P.} and Diane Hopkins and Wenbo Zhi and Boying Dun and Wallbillich, {John Joseph} and Cummings, {Richard D.} and Wang, {Peng George} and Jin-Xiong She",
note = "Funding Information: We would like to thanks all the staff from Cervicusco clinic, Peru for their support and help in recruiting patients and collection of samples and clinical data. Conception and design: JXS and SP; Provision of study patients: DGF, MA and JXS; Provision of glycans: PGW and RDC; Data acquisition: SP, JXS and DGF; Data analysis and interpretation: SP, PMHT, LKHT, DPM, BD, WZ, JJW and JXS; Manuscript writing: All authors; Final approval of manuscript: All authors. This work was supported by National Institutes of Health (NIH)/National Cancer Institute (NCI) grants 1 R21 CA199868 (JXS and SP), U01CA221242 (JXS and SP), P41GM103694 (RDC) and NIH fellowships F30DK12146101A1 (PMHT), K12HD085817 (JJW). JXS was supported by the Georgia Research Alliance Academy. The Funding agencies have no involvement in conception, design, collection and interpretation, publishing of the data. Funding Information: This work was supported by National Institutes of Health (NIH)/National Cancer Institute (NCI) grants 1 R21 CA199868 (JXS and SP), U01CA221242 (JXS and SP), P41GM103694 (RDC) and NIH fellowships F30DK12146101A1 (PMHT), K12HD085817 (JJW). JXS was supported by the Georgia Research Alliance Academy. The Funding agencies have no involvement in conception, design, collection and interpretation, publishing of the data. Appendix A Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",
year = "2020",
month = apr,
doi = "10.1016/j.ygyno.2020.01.014",
language = "English (US)",
volume = "157",
pages = "181--187",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",
}
